Tags : Atomwise

Weekly Snapshot

PharmaShots Weekly Snapshot (March 09-13, 2020)

1. I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19 Published: Mar 13, 2020 | Tags: I-Mab, Initiate, Development, TJM2, Treating, Cytokine Release Syndrome, COVID-19 2. EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (December 02-06, 2019)

1.  Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major Depressive Disorders  2. UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis Published: Dec 06, 2019 | Tags: UCB, […]Read More


StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting

Shots: Joint Venture will combine StemoniX’s human microOrgan platform with Atomwise’s AI technology to allow the rapid discovery and development of novel therapies, initially targeting Rett syndrome Atomwise will utilize its AI technology for identifying potent and selective binders for protein targeting Rett syndrome while StemoniX will test the compounds on its human microBrain 3D […]Read More


Pfizer and Atomwise Signs an Evaluation Agreement to Identify Potential

Shots: Pfizer will pay access fee for using Atomwise’s AI technology with success-based payments for each target protein selected, while Atomwise will computationally analyse various small molecules for each of Pfizer’s identified target proteins Additionally, Atomwise medicinal and computational chemistry team will work collaboratively with Pfizer scientists to identify potency and chemical properties of the […]Read More